Literature DB >> 25394016

Large disparities in HIV treatment cascades between eight European and high-income countries - analysis of break points.

Alice Raymond1, Andrew Hill2, Anton Pozniak3.   

Abstract

INTRODUCTION: Patients on antiretroviral treatment with undetectable HIV RNA levels have a significantly lower risk of clinical disease progression and onward HIV transmission. This study aimed to estimate and compare the percentage of all HIV-positive people who are diagnosed, are linked to care, are taking antiretroviral treatment and have undetectable HIV RNA, in eight European and high-income countries: the United States, the United Kingdom, France, the Netherlands, Denmark, Australia, British Columbia (Canada) and Georgia.
MATERIALS AND METHODS: For each country, the number of people in five key stages of the HIV treatment cascade was collected: 1. HIV infected, 2. Known to be HIV positive, 3. Linked to care, 4. Taking antiretroviral treatment, and 5. Having undetectable HIV RNA. Estimates were extracted from national reports (1-3), the UNAIDS database, conference proceedings (4) and peer-reviewed articles (5-7). The quality of the estimates and reporting methods were assessed individually for each country, with selection criteria such as availability of nationwide database and routinely collected data. Treatment cascades were constructed using estimates from 2010 to 2012.
RESULTS: As shown in Table 1, the percentage of all infected people with undetectable HIV RNA ranged from 20% in Georgia to 59% in Denmark. Of the high-income countries, the United States has the lowest percentage of individuals with undetectable viral load (25% to median 52%), associated with the highest HIV incidence rate (15.30 per 100,000 to median 6.07 per 100,000). The pattern of the cascades differed between countries: in the United States, there is a fall from 66% to 33% (-33%) between linkage to care and start of antiretroviral treatment. However, in Georgia, the greatest loss in continuum was zat diagnosis, with 48% of undiagnosed HIV-positive individuals.
CONCLUSIONS: There are great disparities among European and high-income countries in the percentage of HIV-positive individual with undetectable HIV RNA. Furthermore, the treatment cascades show different key break points, underlying inequalities in HIV care between countries.

Entities:  

Year:  2014        PMID: 25394016      PMCID: PMC4224795          DOI: 10.7448/IAS.17.4.19507

Source DB:  PubMed          Journal:  J Int AIDS Soc        ISSN: 1758-2652            Impact factor:   5.396


HIV treatment cascades in eight European and high-income countries
Table 1

HIV treatment cascades in eight European and high-income countries

CountriesFranceNetherlandsUnited StatesUnited KingdomAustraliaBritish ColumbiaDenmarkGeorgia
Number living with HIV149,90025,0001,148,20098,40033,00011,70065004900
Percentage diagnosed818275718552
Percentage linked to care>74736679678144
Percentage on ART>6059336735516226
Percentage with undetectable HIV RNA5253255832355920
  3 in total

1.  The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study.

Authors:  Bohdan Nosyk; Julio S G Montaner; Guillaume Colley; Viviane D Lima; Keith Chan; Katherine Heath; Benita Yip; Hasina Samji; Mark Gilbert; Rolando Barrios; Réka Gustafson; Robert S Hogg
Journal:  Lancet Infect Dis       Date:  2013-09-27       Impact factor: 25.071

2.  Differences in human immunodeficiency virus care and treatment among subpopulations in the United States.

Authors:  H Irene Hall; Emma L Frazier; Philip Rhodes; David R Holtgrave; Carolyn Furlow-Parmley; Tian Tang; Kristen Mahle Gray; Stacy M Cohen; Jonathan Mermin; Jacek Skarbinski
Journal:  JAMA Intern Med       Date:  2013-07-22       Impact factor: 21.873

3.  HIV care in the Swedish-Danish HIV cohort 1995-2010, closing the gaps.

Authors:  Marie Helleberg; Amanda Häggblom; Anders Sönnerborg; Niels Obel
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

  3 in total
  22 in total

1.  The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa.

Authors:  Rochelle P Walensky; Ethan D Borre; Linda-Gail Bekker; Stephen C Resch; Emily P Hyle; Robin Wood; Milton C Weinstein; Andrea L Ciaranello; Kenneth A Freedberg; A David Paltiel
Journal:  Ann Intern Med       Date:  2016-05-31       Impact factor: 25.391

2.  Loss to Follow-up Trends in HIV-Positive Patients Receiving Antiretroviral Treatment in Asia From 2003 to 2013.

Authors:  Nicole L De La Mata; Penh S Ly; Kinh V Nguyen; Tuti P Merati; Thuy T Pham; Man P Lee; Jun Y Choi; Jeremy Ross; Matthew G Law; Oon T Ng
Journal:  J Acquir Immune Defic Syndr       Date:  2017-04-15       Impact factor: 3.731

3.  Estimating antiretroviral treatment coverage rates and viral suppression rates for homosexual men in Australia.

Authors:  Nicole L De La Mata; Limin Mao; John De Wit; Don Smith; Martin Holt; Garrett Prestage; David P Wilson; Kathy Petoumenos
Journal:  Sex Health       Date:  2015-10       Impact factor: 2.706

4.  The Association of Unmet Needs With Subsequent Retention in Care and HIV Suppression Among Hospitalized Patients With HIV Who Are Out of Care.

Authors:  Dima Dandachi; Sarah B May; Jessica A Davila; Jeffrey Cully; K Rivet Amico; Michael A Kallen; Thomas P Giordano
Journal:  J Acquir Immune Defic Syndr       Date:  2019-01-01       Impact factor: 3.731

5.  Barriers and Facilitators of HIV Care Engagement: Results of a Qualitative Study in St. Petersburg, Russia.

Authors:  Anna V Kuznetsova; Anastasia Y Meylakhs; Yuri A Amirkhanian; Jeffrey A Kelly; Alexey A Yakovlev; Vladimir B Musatov; Anastasia G Amirkhanian
Journal:  AIDS Behav       Date:  2016-10

6.  The Price of Prevention: Cost Effectiveness of Biomedical HIV Prevention Strategies in South Africa.

Authors:  Nishila Moodley; Glenda Gray; Melanie Bertram
Journal:  Clin Res HIV AIDS       Date:  2016-11-27

Review 7.  The HIV care cascade: a systematic review of data sources, methodology and comparability.

Authors:  Nicholas A Medland; James H McMahon; Eric P F Chow; Julian H Elliott; Jennifer F Hoy; Christopher K Fairley
Journal:  J Int AIDS Soc       Date:  2015-11-30       Impact factor: 5.396

8.  Poor Linkage to Care Despite Significant Improvement in Access to Early cART in Central Poland - Data from Test and Keep in Care (TAK) Project.

Authors:  Justyna D Kowalska; Leah Shepherd; Magdalena Ankiersztejn-Bartczak; Aneta Cybula; Hanna Czeszko-Paprocka; Ewa Firląg-Burkacka; Amanda Mocroft; Andrzej Horban
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

9.  Implementation and Operational Research: Engagement in HIV Care Among Persons Enrolled in a Clinical HIV Cohort in Ontario, Canada, 2001-2011.

Authors:  Ann N Burchell; Sandra Gardner; Lucia Light; Brooke M Ellis; Tony Antoniou; Jean Bacon; Anita Benoit; Curtis Cooper; Claire Kendall; Mona Loutfy; Frank McGee; Janet Raboud; Anita Rachlis; Wendy Wobeser; Sean B Rourke
Journal:  J Acquir Immune Defic Syndr       Date:  2015-09-01       Impact factor: 3.731

10.  Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine within a Comprehensive HIV/AIDS Response in Low- and Middle-Income Countries.

Authors:  Thomas M Harmon; Kevin A Fisher; Margaret G McGlynn; John Stover; Mitchell J Warren; Yu Teng; Arne Näveke
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.